Voest EE - Search Results

1

Genomic and transcriptomic plasticity in treatment-naive ovarian cancer.

Hoogstraat M, de Pagter MS, Cirkel GA, van Roosmalen MJ, Harkins TT, Duran K, Kreeftmeijer J, Renkens I, Witteveen PO, Lee CC, Nijman IJ, Guy T, van 't Slot R, Jonges TN, Lolkema MP, Koudijs MJ, Zweemer RP, Voest EE, Cuppen E, Kloosterman WP. Hoogstraat M, et al. Among authors: voest ee. Genome Res. 2014 Feb;24(2):200-11. doi: 10.1101/gr.161026.113. Epub 2013 Nov 12. Genome Res. 2014. PMID: 24221193 Free PMC article.

2

[The clinical perspective of angiogenesis inhibitors].

Radema SA, Witteveen PO, Gebbink MB, Voest EE. Radema SA, et al. Among authors: voest ee. Ned Tijdschr Geneeskd. 2003 Aug 30;147(35):1675-80. Ned Tijdschr Geneeskd. 2003. PMID: 14513538 Review. Dutch.

3

Fibronectin is a hypoxia-independent target of the tumor suppressor VHL.

Bluyssen HA, Lolkema MP, van Beest M, Boone M, Snijckers CM, Los M, Gebbink MF, Braam B, Holstege FC, Giles RH, Voest EE. Bluyssen HA, et al. Among authors: voest ee. FEBS Lett. 2004 Jan 2;556(1-3):137-42. doi: 10.1016/s0014-5793(03)01392-9. FEBS Lett. 2004. PMID: 14706840 Free article.

4

The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery.

Lolkema MP, Mehra N, Jorna AS, van Beest M, Giles RH, Voest EE. Lolkema MP, et al. Among authors: voest ee. Exp Cell Res. 2004 Dec 10;301(2):139-46. doi: 10.1016/j.yexcr.2004.07.016. Exp Cell Res. 2004. PMID: 15530850

5

Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain.

Lolkema MP, Gervais ML, Snijckers CM, Hill RP, Giles RH, Voest EE, Ohh M. Lolkema MP, et al. Among authors: voest ee. J Biol Chem. 2005 Jun 10;280(23):22205-11. doi: 10.1074/jbc.M503220200. Epub 2005 Apr 11. J Biol Chem. 2005. PMID: 15824109 Free article.

6

Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis.

Giles RH, Lolkema MP, Snijckers CM, Belderbos M, van der Groep P, Mans DA, van Beest M, van Noort M, Goldschmeding R, van Diest PJ, Clevers H, Voest EE. Giles RH, et al. Among authors: voest ee. Oncogene. 2006 May 18;25(21):3065-70. doi: 10.1038/sj.onc.1209330. Oncogene. 2006. PMID: 16407833

7

Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors.

Kuppens IE, Witteveen PO, Schot M, Schuessler VM, Daehling A, Beijnen JH, Voest EE, Schellens JH. Kuppens IE, et al. Among authors: voest ee. Invest New Drugs. 2007 Jun;25(3):227-35. doi: 10.1007/s10637-006-9027-2. Epub 2006 Dec 5. Invest New Drugs. 2007. PMID: 17146730 Clinical Trial.

8

[Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors].

Tjin-A-ton ML, van Montfrans C, Koldenhof JJ, Sigurdsson V, Voest EE, Witteveen PO. Tjin-A-ton ML, et al. Among authors: voest ee. Ned Tijdschr Geneeskd. 2007 Apr 28;151(17):945-52. Ned Tijdschr Geneeskd. 2007. PMID: 17520845 Dutch.

9

The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2.

Lolkema MP, Mans DA, Snijckers CM, van Noort M, van Beest M, Voest EE, Giles RH. Lolkema MP, et al. Among authors: voest ee. FEBS Lett. 2007 Oct 2;581(24):4571-6. doi: 10.1016/j.febslet.2007.08.050. Epub 2007 Aug 31. FEBS Lett. 2007. PMID: 17825299 Free article.

10

Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor.

Lolkema MP, Mans DA, Ulfman LH, Volpi S, Voest EE, Giles RH. Lolkema MP, et al. Among authors: voest ee. Eur J Hum Genet. 2008 Jan;16(1):73-8. doi: 10.1038/sj.ejhg.5201930. Epub 2007 Oct 3. Eur J Hum Genet. 2008. PMID: 17912253

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

354 results

Search Page